Pfizer squeezes out positive data for fructose-fighting NASH drug

An experimental Pfizer drug has scored positive data in a mid-stage clinical trial of patients with fatty liver disease, a precursor condition to the now intensely studied non-alcoholic steatohepatitis, or NASH.